Novartis Reiterates Phase 3 Commitment to Pacibekitug IL-6 Inhibitor Despite Novo Nordisk Ziltivekimab ZEUS Failure; $1.4B Tourmaline Bio Acquisition Backing
Novartis (NYSE: NVS) reiterated at ESC Congress 2026 Saturday August 29 that it will advance the Phase 3 program for pacibekitug (an anti-IL-6 monoclonal antibody acquired from Tourmaline Bio through the $1.4 billion acquisition completed earlier in 2026) for cardiovascular risk reduction in inflammation-driven disease, notwithstanding the Phase 3 ZEUS trial failure of Novo Nordisk's ziltivekimab announced the same weekend. Novartis's stance is that ZEUS was underpowered in the specific ASCVD-plus-CKD-plus-inflammation subgroup rather than a class-level miss for IL-6 blockade, and that pacibekitug's differentiated pharmacokinetic profile (longer half-life and less frequent dosing) plus the differently-selected patient population in the planned Phase 3 will allow the mechanism to prove out. The commitment is a $1.4 billion acquisition-scale bet against the base-rate signal from ZEUS and continues the pattern of large pharma anti-inflammatory cardiovascular pipeline commitment following the earlier successful CANTOS canakinumab (IL-1β) proof of concept.